DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016" report to their offering.
Toll Like Receptor 4 (CD284 or TLR4) pipeline Target constitutes close to 36 molecules. Out of which approximately 32 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Toll Like Receptor 4 - Pipeline Review, H1 2016, outlays comprehensive information on the Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Toll Like Receptor 4 (CD284 or TLR4) Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL). The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 2, 19 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Furthermore, this report also reviews key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
- Toll Like Receptor 4 Overview
- Therapeutics Development
- Pipeline Products for Toll Like Receptor 4 - Overview
- Pipeline Products for Toll Like Receptor 4 - Comparative Analysis
- Toll Like Receptor 4 - Therapeutics under Development by Companies
- Toll Like Receptor 4 - Therapeutics under Investigation by Universities/Institutes
- Toll Like Receptor 4 Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Toll Like Receptor 4 - Products under Development by Companies
- Toll Like Receptor 4 - Products under Investigation by Universities/Institutes
- Toll Like Receptor 4 - Companies Involved in Therapeutics Development
- Batu Biologics, Inc.
- BioLineRx, Ltd.
- Biomedica Management Corporation
- Eisai Co., Ltd.
- eTheRNA Immunotherapies NV
- Formune S.L.
- GlaxoSmithKline Plc
- Harbor Therapeutics, Inc.
- Immune Design Corp.
- Immunovo BV
- Kyorin Pharmaceutical Co., Ltd.
- NovImmune SA
- Reliance Life Sciences Pvt. Ltd.
- TaiwanJ Pharmaceuticals Co., Ltd.
- Vascular Biogenics Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/545255/toll_like
Related Topics: Immune Disorders Drugs